PubRank

Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma

Clinical Trial ID NCT01686386

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01686386

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International uniform response criteria for multiple myeloma. Leukemia 2006 17.78
2 National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 13.35
3 Cancer statistics, 2002. CA Cancer J Clin 2002 10.79
4 Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005 8.80
5 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 8.77
6 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 8.41
7 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 8.16
8 Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2009 5.73
9 Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006 3.95
10 Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2007 2.80
11 Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2007 2.76
12 Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 2.68
13 Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008 2.32
14 Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008 2.27
15 Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol 2007 2.14
16 Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007 1.50
17 Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006 1.42
18 Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol 2008 1.03
19 The epidemiology of multiple myeloma. Semin Hematol 2001 0.86
20 [Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride]. Dtsch Med Wochenschr 1969 0.79
21 Thalidomide in multiple myeloma. N Engl J Med 2000 0.75
Next 100